Literature DB >> 12914679

The role of the N-methyl-D-aspartate receptor in Alzheimer's disease: therapeutic potential.

P Murali Doraiswamy1.   

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder with an unknown etiology. Pathologic processes implicated in AD include b-amyloid-induced synaptic failure; tau hyperphosphorylation; inflammation; oxidative stress; abnormal neurotransmission involving acetylcholine, glutamate, norepinephrine, serotonin, and dopamine; and abnormalities in second messengers, protein kinases, and apoptosis. Although each of these pathways offers potential therapeutic targets, pharmacologic manipulation of the glutamatergic N-methyl-D-aspartate receptor pathway, alone or in combination with cholinergic therapies, is emerging as the next promising strategy for the treatment of AD and vascular dementia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12914679     DOI: 10.1007/s11910-003-0019-8

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  57 in total

1.  Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.

Authors:  M W Dysken; J Mendels; P LeWitt; B Reisberg; N Pomara; J Wood; S Skare; J D Fakouhi; R L Herting
Journal:  J Am Geriatr Soc       Date:  1992-05       Impact factor: 5.562

2.  The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

Authors:  G Blessed; B E Tomlinson; M Roth
Journal:  Br J Psychiatry       Date:  1968-07       Impact factor: 9.319

3.  Generation of aggregated beta-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits.

Authors:  A Stéphan; S Laroche; S Davis
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

Review 4.  Evaluation of memantine for neuroprotection in dementia.

Authors:  K K Jain
Journal:  Expert Opin Investig Drugs       Date:  2000-06       Impact factor: 6.206

5.  Development and selective neurodegeneration in cell cultures from different hippocampal regions.

Authors:  M P Mattson; S B Kater
Journal:  Brain Res       Date:  1989-06-19       Impact factor: 3.252

6.  Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial.

Authors:  J Grotta; W Clark; B Coull; L C Pettigrew; B Mackay; L B Goldstein; I Meissner; D Murphy; L LaRue
Journal:  Stroke       Date:  1995-04       Impact factor: 7.914

7.  Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity.

Authors:  S T DeKosky; S W Scheff
Journal:  Ann Neurol       Date:  1990-05       Impact factor: 10.422

8.  Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat.

Authors:  G L Wenk; W Danysz; S L Mobley
Journal:  Brain Res       Date:  1994-08-29       Impact factor: 3.252

9.  Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus.

Authors:  G L Collingridge; S J Kehl; H McLennan
Journal:  J Physiol       Date:  1983-01       Impact factor: 5.182

10.  Effects of NMDA modulation in scopolamine dementia.

Authors:  R W Jones; K A Wesnes; J Kirby
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

View more
  5 in total

1.  Memantine approved to treat moderate to severe Alzheimer's disease.

Authors:  Karen Marder
Journal:  Curr Neurol Neurosci Rep       Date:  2004-09       Impact factor: 5.081

Review 2.  Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology.

Authors:  Timothy J Revett; Glen B Baker; Jack Jhamandas; Satyabrata Kar
Journal:  J Psychiatry Neurosci       Date:  2013-01       Impact factor: 6.186

3.  Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: implications in physiological functions and in pathology.

Authors:  L Ciranna
Journal:  Curr Neuropharmacol       Date:  2006-04       Impact factor: 7.363

4.  Potential of chromatin modifying compounds for the treatment of Alzheimer's disease.

Authors:  Tom C Karagiannis; Katherine Ververis
Journal:  Pathobiol Aging Age Relat Dis       Date:  2012-02-20

5.  A graph neural network model to estimate cell-wise metabolic flux using single-cell RNA-seq data.

Authors:  Norah Alghamdi; Wennan Chang; Pengtao Dang; Xiaoyu Lu; Changlin Wan; Silpa Gampala; Zhi Huang; Jiashi Wang; Qin Ma; Yong Zang; Melissa Fishel; Sha Cao; Chi Zhang
Journal:  Genome Res       Date:  2021-07-22       Impact factor: 9.043

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.